ATE531809T1 - Neues simianes t-zell-lymphotropes virus - Google Patents

Neues simianes t-zell-lymphotropes virus

Info

Publication number
ATE531809T1
ATE531809T1 AT08755984T AT08755984T ATE531809T1 AT E531809 T1 ATE531809 T1 AT E531809T1 AT 08755984 T AT08755984 T AT 08755984T AT 08755984 T AT08755984 T AT 08755984T AT E531809 T1 ATE531809 T1 AT E531809T1
Authority
AT
Austria
Prior art keywords
subtype
stlv
polypeptides
disclosed
nucleic acid
Prior art date
Application number
AT08755984T
Other languages
English (en)
Inventor
William Switzer
Walid Heneine
Thomas Folks
Nathan Wolfe
Donald Burke
David Sintasath
Original Assignee
Gov Of The Usa As Represented By The Secretary Of The Dept Of Health & Human Services
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gov Of The Usa As Represented By The Secretary Of The Dept Of Health & Human Services, Univ Johns Hopkins filed Critical Gov Of The Usa As Represented By The Secretary Of The Dept Of Health & Human Services
Application granted granted Critical
Publication of ATE531809T1 publication Critical patent/ATE531809T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
AT08755984T 2007-05-21 2008-05-20 Neues simianes t-zell-lymphotropes virus ATE531809T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93930407P 2007-05-21 2007-05-21
US99013807P 2007-11-26 2007-11-26
PCT/US2008/064270 WO2008144700A2 (en) 2007-05-21 2008-05-20 Simian t-cell lymphotropic virus type 3 west african subtype d

Publications (1)

Publication Number Publication Date
ATE531809T1 true ATE531809T1 (de) 2011-11-15

Family

ID=39760969

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08755984T ATE531809T1 (de) 2007-05-21 2008-05-20 Neues simianes t-zell-lymphotropes virus

Country Status (6)

Country Link
US (2) US8663968B2 (de)
EP (1) EP2147110B1 (de)
AT (1) ATE531809T1 (de)
AU (1) AU2008254612B2 (de)
CA (1) CA2688724C (de)
WO (1) WO2008144700A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110000544A1 (en) * 2009-07-02 2011-01-06 West John R Drop-in connection apparatus, system, and method for photovoltaic arrays
CN115852058A (zh) * 2022-12-23 2023-03-28 苏州药明检测检验有限责任公司 一种检测猴t细胞嗜淋巴细胞病毒的引物和探针组合及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510238A (en) * 1984-10-26 1996-04-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Production of human T-cell leukemia (lymphotropic) retrovirus (HTLV-I) envelope protein fragments in bacteria and use in seroepidemiological studies
US4753873A (en) * 1986-02-03 1988-06-28 Cambridge Bioscience Corporation Peptides for the diagnosis of HTLV-III antibodies, their preparation and use
US4879212A (en) * 1986-04-02 1989-11-07 United Biomedical Inc. Peptide composition and method for the detection of antibodies to HTLV-III
US4816387A (en) * 1986-06-06 1989-03-28 Bio-Research Laboratories, Inc. Method for detection of antibodies to HTLV-III and diagnostic test kit useful therewith
US6406841B1 (en) * 1993-07-01 2002-06-18 Abbott Laboratories Methods for the detection of HTLV-II antibodies employing novel HTLV-II NRA envelope peptides
CA2598547C (en) 2005-02-21 2016-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Primate t-lymphotropic viruses

Also Published As

Publication number Publication date
CA2688724C (en) 2016-03-29
WO2008144700A2 (en) 2008-11-27
US20140186383A1 (en) 2014-07-03
EP2147110B1 (de) 2011-11-02
CA2688724A1 (en) 2008-11-27
AU2008254612A2 (en) 2010-01-28
WO2008144700A3 (en) 2009-01-08
AU2008254612B2 (en) 2012-12-13
US8663968B2 (en) 2014-03-04
US20100160420A1 (en) 2010-06-24
EP2147110A2 (de) 2010-01-27
AU2008254612A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
Dijkman et al. Replication-dependent downregulation of cellular angiotensin-converting enzyme 2 protein expression by human coronavirus NL63
SG11201810014UA (en) Viral particle for rna transfer, especially into cells involved in immune response
NO20043891L (no) Anti-A-beta-antistoffer og deres anvendelse
WO2008140812A3 (en) Compositions and methods comprising klk3, psca, or folh1 antigen
WO2011060242A3 (en) Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
WO2005056584A3 (fr) Nouvelle souche de coronavirus associe au sras et ses applications.
CL2012003196A1 (es) Anticuerpo aislado o fragmento del mismo que se une específicamente a interleuquina-4 (il-4); molécula de ácido nucleico aislado que lo codifica y vector que la comprende; célula que comprende dicho vector; composición farmacéutica que comprende dicho anticuerpo; y su uso parar tratar una enfermedad alérgica, cáncer y asma.
SI1685243T1 (sl) Imortalizirane ptičje celične linije za produkcijo virusov
WO2007019094A3 (en) Modified influenza virus for monitoring and improving vaccine efficiency
EA201491051A1 (ru) Вакцины против вируса гриппа и их применения
WO2007084583A3 (en) Soluble fragments of the sars-cov spike glycoprotein
CY1112924T1 (el) Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης
WO2012018907A3 (en) Polypeptides for treating and/or limiting influenza infection
WO2007118206A3 (en) Canine influenza virus
NO20065084L (no) Interferon-alfa polypeptider og konjugater
EA202190267A1 (ru) Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
NZ583783A (en) Avian interferon-lambda polypeptide and genetic sequences encoding the same
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
CY1114618T1 (el) Βιολογικα δραστικα πεπτιδια που περιεχουν καρβοξυτελικη αργινινη
ATE470673T1 (de) Impfstoffe mit lawsoniaintrazellularis- untereinheit
WO2021159129A3 (en) Compositions and methods for circular rna expression
ATE542915T1 (de) Cst-ii-modifzierungen für erhöhte proteinexpression
WO2008144700A3 (en) Simian t-cell lymphotropic virus type 3 west african subtype d
ATE471169T1 (de) Engineering mit homing-faktoren
WO2013138259A3 (en) Polypeptides for treating and/or limiting influenza infection